Aarti Drugs Limited has announced an interim dividend of ₹2 per share (20%) for the financial year 2025-26. The record date for the dividend payment is February 9, 2026. The company also approved the inclusion of key functional heads as Senior Management Personnel, effective February 3, 2026, following recent organizational changes.
Interim Dividend Declared
The Board of Directors has approved an interim dividend of ₹2 per equity share (20%) for the fiscal year 2025-26. This decision reflects the company’s strong financial performance and commitment to delivering shareholder value. The dividend will be paid to shareholders on record as of February 9, 2026.
Senior Management Appointments
Aarti Drugs has also expanded its list of Senior Management Personnel to include key functional heads. This decision, effective February 3, 2026, aligns with the company’s recent organizational restructuring and broader responsibilities for these roles:
- Shri Arun M. Patil, Vice President – Marketing
- Shri Digvir Jadeja, Vice President – Export Marketing
- Shri Jatin Chheda, Manager – Purchase
Financial Results Overview
The Board of Directors approved the audited standalone and consolidated financial results for Q3 (Oct-Dec) 2025 and the nine-month period ended December 31, 2025. Key figures from the standalone results include:
- Revenue from operations: ₹52,880 lakhs
- Profit before tax: ₹2,171 lakhs
- Profit after tax: ₹3,384 lakhs
- Earnings per share: ₹3.71
Source: BSE
